Acute Viral Infections of the Central Nervous System in Immunocompetent Adults: Diagnosis and Management
Abstract
Patients with viral infections of the central nervous system (CNS) may present with a variety of neurological symptoms, most commonly dominated by either encephalitis or meningitis. The aetiological panorama varies in different parts of the world as well as over time. Thus, virological first-line diagnostics must be adapted to the current epidemiological situation and to the individual patient history, including recent travels. This review focuses on the diagnostics and treatment of viral CNS infections in the immunocompetent host from a Northern European perspective. Effective vaccines are available for viruses such as poliovirus and tick-borne encephalitis virus (TBEV) and for the childhood diseases morbilli (measles), rubella (German measles), parotitis (mumps) and varicella (chickenpox). However, cases do appear due to suboptimal immunization rates. In viral CNS infections, epidemiological surveillance is essential for establishing preventive strategies and for detecting emerging viruses. Knowledge of the possibilities and limitations of diagnostic methods for specific viral CNS infections is vital. A positive cerebral spinal fluid (CSF) polymerase chain reaction (PCR) finding is usually reliable for aetiological diagnosis. The demonstration of intrathecal antibody synthesis is useful for confirming the aetiology in a later stage of disease, hitherto sufficiently evaluated in herpes simplex encephalitis (HSE) and tick-borne encephalitis (TBE). Despite improved virological and differential diagnostic methods, aetiology remains unknown in about half of the cases with suspected viral encephalitis. Antiviral treatment is available chiefly for infections caused by herpesviruses, and acyclovir (aciclovir) is the drug of choice for empirical therapy in suspected viral encephalitis. However, randomized, controlled antiviral trials have only been conducted for HSE, while such studies are lacking in other viral CNS infections. Viral cytolysis and immune-mediated mechanisms may contribute to varying extents to neurological damage. Although the brain damage is believed to depend, to a varying degree, on the intrathecal host immune response, the use of corticosteroids in viral CNS infections is scarcely studied, as is specific treatment for neuroinflammation. Improved antiviral and immunomodulating treatment is desirable. Since neurological sequelae are still abundant, follow-up after severe viral CNS disease must include a neuropsychological assessment and an individually adapted rehabilitation plan.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HHV-6 can cause severe CNS disease, especially in immunocompromised hosts, but a positive HHV-6 finding may also result from subclinical reactivation of the latent virus or chromosomal integration and may not be relevant for the CNS infection.
“Although HHV-6 can cause severe CNS disease, especially in immunocompromised hosts, a positive HHV-6 finding may also result from subclinical reactivation of the latent virus or chromosomal integration and may not be relevant for the CNS infection (26–29).”
From Evaluation of the Novel CE-IVD-Marked Multiplex PCR QIAstat-Dx Meningitis/Encephalitis Panel (2023) · cites this paper as [27]
The citation lists haven’t been fetched yet
References 262 · Cited by 90
- Authors
- Studahl, M., Lindquist, L., Eriksson, B.-M., Günther, G., Bengner, M., Franzen-Röhl, E., Fohlman, J., Bergström, T., & Aurelius, E.
- Affiliations
- University of Gothenburg (SE)
- Karolinska University Hospital (SE)
- Uppsala University (SE)
- Växjö Kommun (SE)
- Corresponding author
- Studahl, Marie
- Venue
- Drugs
- Published
- 2013-02
- Volume
- 73
- Issue
- 2
- Pages
- 131-158
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W1965477305
- Cited by
- 90
- References
- 262
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 10 · 2022: 7 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 3
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sahlgrenska Universitetssjukhuset
- Topics
- Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- viral encephalitis, viral meningitis, central nervous system infection, immunocompetent adult, herpes simplex encephalitis, tick-borne encephalitis, intrathecal antibody synthesis, cerebrospinal fluid PCR, acyclovir, antiviral therapy, corticosteroids, neuroinflammation, neurological sequelae, neuropsychological follow-up, rehabilitation, vaccination, emerging viruses, disease surveillance
- MeSH terms
- Acute Disease, Adult, Antiviral Agents, Diagnosis, Differential, Humans, Immunocompetence, Randomized Controlled Trials as Topic, Central Nervous System Viral Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review